ArticleScientific reports2026
Single cell RNA transcriptome response to fentanyl use in persons with HIV infection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The US is experiencing a major drug epidemic largely attributed to synthetic opioids including fentanyl. We considered how illicit fentanyl use in persons living with HIV impacted gene expression profiles in the peripheral blood. Whole blood was collected from 10 HIV-positive adults with a diagnosis of opioid use disorder (OUD) and 7 HIV-positive non-opioid using controls. Mean HIV viral loads were higher for the OUD+ group, although this difference did not reach statistical significance (2.44 versus 1.00 log10 copies/mL; p = 0.12; two-sample T test). 216,641 cells were evaluated by single cell RNAseq. Cell frequencies were not different by opioid status except for NK cells (lower for opioid use; p = 0.0045). For CD4+ T lymphocytes, 10 differentially expressed genes (DEGs) were higher and 8 were lower in opioid-positive persons. In CD8+ T lymphocytes, there were 15 higher and 13 lower DEGs for opioid-positive study participants. In monocytes, 72 DEGs were higher and 37 DEGs were lower in opioid-positive participants. In B lymphocytes, 17 DEGs were higher and 10 were lower in opioid-positive versus opioid-negative participants. These findings highlight multiple pathways by which opioid use may contribute to HIV pathogenesis. Rigorous characterization of the interactions among HIV, opioids, and host cells can improve clinical management paradigms, facilitate rational public health policies, and reveal additional pathways for novel target-specific therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.